Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2517 -0.1227%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%

Blocking `Rogue Gene' Could Stop Spread of Cancer, U.K. Researchers Find

Scientists have identified a “rogue gene” that attacks and breaks down a protein that naturally occurs in the body and normally prevents cancer cells from spreading.

Blocking the gene, known as WWP2, results in higher levels of the protein, which in turn renders cancer cells dormant, researchers led by Andrew Chantry, a scientist at the University of East Anglia’s School of Biological Sciences, wrote in a paper published in Nature Publishing Group’s cancer journal Oncogene.

The discovery may, within the next decade, lead to a new generation of drugs to stop the most aggressive forms of cancer, including breast, brain, colon and skin tumors, the researchers said. The development of medicines that deactivated WWP2 would mean that existing drugs and surgery could be used on primary tumors, with no risk of the disease spreading elsewhere, the authors said.

“The challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,” Chantry said in a statement from the university, based in Norwich, England. “This is a difficult but not impossible task.”

The research was funded by the St. Andrews, Scotland-based Association of International Cancer Research, with support from the Big C Charity in Norwich and the British Skin Foundation.

To contact the reporter on this story: Carey Sargent in Geneva at csargent3@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Sponsored Links